ClinicalTrials.gg
RecruitingNCT05686642Updated Apr 30, 2026

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

A Phase 2 interventional study of LT3001 Drug:high dose and Placebo in Acute Ischemic Stroke, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 28 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
258th of 563
300 · median 266
Started
2023
with 91 others
Phase 2
71 of 750
29 open now
Primary completion
2026-12
later than 152 of 395 live
Registered
325th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 258th largest by planned enrollment of the 563 interventional ones that give a count, is one of 92 that started in 2023, is one of 71 in phase 2, reaches primary completion later than 152 of the 395 other live ones, and was the 325th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged between 18 and 80 years at screening;
  2. Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization;

4.Subjects who are able to receive the drug within 24 hours after the onset of stroke; 5.Female subjects of or male subjects whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective measures during the study period and for 3 months after the last dose; 6.All subjects sign the form by themselves or their guardians after receiving complete study information.

Exclusion criteria

Exclusion Criteria:

  1. Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period;
  2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;
  3. Neurological signs have improved rapidly and spontaneously at screening;
  4. Subjects who have used or are using protocol-prohibited medications after the onset;
  5. Subjects with pre-stroke disability;
  6. Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment;
  7. Massive infarction on imaging;
  8. Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate;
  9. Systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg after active antihypertensive therapy;
  10. Acute hemorrhage tendency;
  11. Blood glucose level \< 50 mg/dL or > 400 mg/dL;
  12. Active visceral hemorrhage;
  13. Lactating or pregnant subjects, or women of with positive pregnancy test results;
  14. > 1.7 or prothrombin time > 15 s;
  15. Subjects with a history of serious ;
  16. Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening;
  17. Subjects who underwent any major surgery before screening;
  18. Subjects with a history of active digestive ulcer before screening;
  19. Subjects who experienced hemorrhagic disease before screening;
  20. Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening;
  21. Serious hepatic impairment or serious renal insufficiency;
  22. Subjects who have participated in another study and used investigational product before screening;
  23. Other conditions unsuitable for participation in this study determined by the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    LT3001 Drug:high dose

    Drug: LT3001 Drug:high dose

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    LT3001 Drug:low dose

    Drug: LT3001 Drug:low dose

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence Adverse Events

    Adverse event type, incidence, duration, correlation with study drug

    Time frame: Approximately 2 years

Secondary outcomes

  1. Proportion of subjects by mRS(Modified Rankin Scale) score (0 - 2)

    Proportion of subjects by mRS score (0 - 2)

    Time frame: Day 30 and Day 90 after the first dose

  2. Proportion of subjects with an NIHSS(National Institute of Health stroke scale ) score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score

    Proportion of subjects with an NIHSS score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score

    Time frame: Day 14 after the first dose

  3. Absolute change from baseline in NIHSS score

    Absolute change from baseline in NIHSS score

    Time frame: Day 3、Day 7、Day 14 and Day 30 after the first dose

  4. Proportion of subjects with a BI(Barthel index) score of ≥ 95 points and ≥ 75 points

    Proportion of subjects with a BI score of ≥ 95 points and ≥ 75 points

    Time frame: Day 30 and Day 90 after the first dose

07

Study locations

28 of 28 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 44 months is above that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 17, 2023
StartActual
Apr 6, 2023
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 12, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05686642
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Apr 6, 2023
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 12, 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Yongjun Wang
Contact
Yongjunwang111@aliyun.com
0086-010-59978538

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LT3001

Start the discussion